These data contrasted with a prior report documenting that ATM inhibition subtly exacerbated doxorubicin toxicity in prostate cancer cells58, and was somewhat surprising, as ATM often activates p53 in doxorubicin-treated cells, either directly or via Chk2 activation62. The gene discussed is TP53; the disease is prostate cancer.